Evidence map›Paper›PMID 27910062›Full record

ArticleJournal of applied genetics2017

Plasma and saliva miR-21 expression in colorectal cancer patients.

A A Sazanov, E V Kiselyova, A A Zakharenko, M N Romanov, M I Zaraysky

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Journal of applied genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 7 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 7 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. [Latest Findings on Salivary Tumor Biomarkers].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

A A SazanovDepartment of Clinical Laboratory Diagnostics with a course of Molecular Medicine, First Pavlov State Medical University of St. Petersburg, 6/8 Lev Tolstoy Street, St. Petersburg, 197022, Russia. alexei.sazanov@technolog.edu.ru.
E V KiselyovaDepartment of Surgery and Emergency Medicine, First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia.
A A ZakharenkoDepartment of Surgery and Emergency Medicine, First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia.
M N RomanovSchool of Biosciences, University of Kent, Canterbury, UK.
M I ZarayskyDepartment of Clinical Laboratory Diagnostics with a course of Molecular Medicine, First Pavlov State Medical University of St. Petersburg, 6/8 Lev Tolstoy Street, St. Petersburg, 197022, Russia.
First Pavlov State Medical University of St. Petersburg · RUUniversity of Kent · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA-21 (miR-21) expression was quantified by real-time qRT-PCR in peripheral blood and saliva samples obtained from patients diagnosed with colorectal cancer (CRC) of varying degrees of malignancy and healthy volunteers. All patients had adenocarcinoma located in the distal colon at different stages. Significant differences were detected between the control group and the total experimental group of CRC patients (plasma, P = 0.0001; saliva, P = 5e-12). MiR-21 expression was also significantly different in certain subgroups of patients with CRC disease stages II-IV as compared to the control group. No correlation of miR-21 expression was found with regard to gender and age of patents. Also, there were no significant individual correlations and linear regression of miR-21 expression in the plasma and saliva. The estimated diagnostic sensitivity and specificity of miR-21 expression were respectively 65 and 85% in the plasma, and 97 and 91% in the saliva. Our data suggest that miR-21 in both the saliva and plasma could be a proper biomarker for CRC screening, although the saliva miR-21 expression test looks preferable due to its higher sensitivity, specificity, and technical simplicity.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCase-Control StudiesColorectal NeoplasmsFemaleHumansMaleMicroRNAsMiddle AgedNeoplasm StagingSalivaSensitivity and SpecificityBiomarkers, TumorMicroRNAsMIRN21 microRNA, humanBlood plasmaColorectal cancerEpigeneticsGene expression profilingmicroRNA (miR)miR-21Molecular diagnosticsReal-time qRT-PCRSaliva

Identifiers

PMID27910062
OpenAlexW2558969828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.